Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study

BACKGROUND: The purpose of this study was to confirm the efficacy and safety of twice-daily glycopyrrolate 15.6 µg, a long-acting muscarinic antagonist, in patients with stable, symptomatic, chronic obstructive pulmonary disease (COPD) with moderate-to-severe airflow limitation. METHODS: The GEM1 st...

Descripción completa

Detalles Bibliográficos
Autores principales: LaForce, Craig, Feldman, Gregory, Spangenthal, Selwyn, Eckert, Joerg H, Henley, Michelle, Patalano, Francesco, D’Andrea, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907493/
https://www.ncbi.nlm.nih.gov/pubmed/27354782
http://dx.doi.org/10.2147/COPD.S100445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907493/
https://www.ncbi.nlm.nih.gov/pubmed/27354782
http://dx.doi.org/10.2147/COPD.S100445

Ejemplares similares